Section 2.1: Asthma & Bronchospastic Disease

Asthma & Bronchospastic Disease

Why This Topic Matters for the PANCE

Asthma is a high-yield diagnostic and management entity on the PANCE pulmonary blueprint, which constitutes 9% of the overall exam. The board exams heavily test the differentiation of asthma from Chronic Obstructive Pulmonary Disease (COPD), the clinical application of step-wise pharmacological guidelines, and the stabilization of acute exacerbations. Crucially, you must be able to recognize signs of impending respiratory arrest, such as a silent chest on auscultation or a rising carbon dioxide level on an arterial blood gas (ABG).

Definitions and Pathophysiology

Asthma is a chronic, reversible inflammatory disease of the airways characterized by bronchial hyperresponsiveness, mucosal edema, and mucous hypersecretion.

The pathophysiology of asthma is predominantly driven by a Type I (IgE-mediated) hypersensitivity reaction, which involves an exaggerated helper T-cell response. Exposure to environmental triggers (such as pollen, animal dander, cold air, exercise, or viral upper respiratory tract infections) stimulates dendritic cells to present antigens to T-helper 2 (Th2) cells. These Th2 cells release a cascade of interleukins:

• IL-4 and IL-13: Stimulate B-lymphocytes to undergo class switching and produce immunoglobulin E (IgE), which then binds to high-affinity receptors on mast cells.
• IL-5: Recruits, activates, and promotes the survival of eosinophils within the respiratory tract.

Upon re-exposure to the sensitizing antigen, the allergen cross-links the IgE bound to mast cells, triggering cellular degranulation:

• Early-Phase Response (within minutes): Characterized by the release of preformed mediators (histamine, leukotrienes C4, D4, and E4, and prostaglandins). These mediators cause immediate contraction of bronchial smooth muscle (bronchospasm), vascular congestion, and increased microvascular permeability leading to mucosal edema.
• Late-Phase Response (4 to 8 hours later): Characterized by the recruitment of inflammatory cells, particularly eosinophils and neutrophils. Eosinophils release cytotoxic proteins, such as major basic protein and eosinophil cationic protein, which damage the airway epithelial lining, impair ciliary function, and cause the secretion of thick, tenacious mucus plugs.
• Airway Remodeling: Over time, persistent and untreated chronic inflammation leads to irreversible structural alterations. These changes include subepithelial fibrosis (thickening of the basement membrane), hypertrophy and hyperplasia of airway smooth muscle, and goblet cell hyperplasia, leading to a fixed, non-reversible component of airflow obstruction.

Risk Factors: The primary risk factor is atopy (the atopic triad: asthma, allergic rhinitis, and atopic dermatitis). Samter's Triad (Aspirin-Exacerbated Respiratory Disease) consists of asthma, nasal polyps, and bronchospastic sensitivity to aspirin and NSAIDs, driven by a shunt of arachidonic acid metabolism into the leukotriene pathway.

Clinical Presentation

Patients present with episodic paroxysms of dyspnea, wheezing, chest tightness, and a dry, hacking cough that is characteristically worse at night or in the early morning.

• Physical Exam Findings: During a mild-to-moderate acute exacerbation, auscultation reveals high-pitched, expiratory wheezing and a prolonged expiratory phase. You will observe tachypnea, tachycardia, hyperresonance to percussion (due to air trapping), and accessory muscle use (intercostal, supraclavicular retractions).
• Impending Respiratory Failure: A "silent chest" (the complete absence of wheezing and breath sounds due to critical airway closure) is a medical emergency. Other red flags include altered mental status (somnolence, agitation), inability to speak in full sentences, and a pulsus paradoxus (a drop in systolic blood pressure > 10 mmHg during inspiration).

Diagnostic Workup

• Spirometry (Pulmonary Function Tests): This is the initial diagnostic test of choice. It reveals an obstructive pattern, defined by a Forced Expiratory Volume in 1 second to Forced Vital Capacity ratio (FEV1/FVC < 0.70).
• Bronchodilator Reversibility: Reversibility is demonstrated by a post-bronchodilator increase in FEV1 of > 12% and > 200 mL after administering a short-acting beta-agonist (SABA, e.g., 4 puffs of albuterol). Significant reversibility points to asthma rather than COPD.
• Methacholine Challenge: Indicated if spirometry is normal but asthma is still clinically suspected. Patients inhale escalating doses of methacholine (a cholinergic agonist). A decline in FEV1 of 20% or more (PC20 <= 8 mg/mL) establishes bronchial hyperresponsiveness.
• Peak Expiratory Flow (PEF) Monitoring: A critical tool for home management. A diurnal PEF variation of > 10% demonstrates variable airflow limitation.
• Fractional Exhaled Nitric Oxide (FeNO): A non-invasive marker of eosinophilic airway inflammation; elevated FeNO (> 50 ppb in adults) supports the diagnosis.

Clinical Management

Asthma Severity Classification

Assess severity prior to initiating controller therapy to guide the initial treatment step:

Step-Wise Management (GINA Guidelines)

Therapy is escalated or de-escalated in a step-wise fashion to maintain control:

• Step 1: As-needed low-dose Inhaled Corticosteroid (ICS) combined with formoterol (a fast-acting LABA) is the preferred rescue. Alternatively, a SABA (e.g., albuterol) can be used as needed.
• Step 2: Daily low-dose ICS (e.g., fluticasone, budesonide) plus SABA PRN, or low-dose ICS-formoterol PRN. Patient education: Rinse mouth and spit after ICS use to prevent oral candidiasis (thrush).
• Step 3: Daily low-dose ICS-LABA (e.g., fluticasone-salmeterol, budesonide-formoterol).
• Step 4: Daily medium-dose ICS-LABA.
• Step 5: Daily high-dose ICS-LABA. Consider adding a Long-Acting Muscarinic Antagonist (LAMA, e.g., tiotropium) or biologic therapies (e.g., omalizumab for elevated IgE).
• Alternative Add-ons: Leukotriene Receptor Antagonists (LTRAs, e.g., montelukast) are useful, especially for exercise-induced asthma. Note the black box warning for neuropsychiatric side effects (agitation, depression, suicidal ideation).

Acute Exacerbation Treatment

• First-line: Nebulized SABA (albuterol) and SAMA (ipratropium bromide) every 20 minutes for 3 doses, plus supplemental oxygen (target saturation 93-95%).
• Systemic Corticosteroids: Oral prednisone (40-50 mg) or IV methylprednisolone (60-125 mg) must be initiated early to resolve airway inflammation.
• IV Magnesium Sulfate: Indicated for severe, refractory bronchoconstriction (2 g IV over 20 minutes).
• Intubation: Indicated for a silent chest, somnolence, or an arterial blood gas (ABG) showing a normal or rising PaCO2 (reflecting respiratory muscle fatigue).

Classic PANCE Traps and Clinical Pearls

• The ABG Trap: Hyperventilating asthma patients should present with respiratory alkalosis (low PaCO2). A normal (35-45 mmHg) or elevated PaCO2 is an ominous sign indicating diaphragmatic fatigue. Prepare for immediate intubation.
• Beta-Blocker Contraindication: Non-selective beta-blockers (e.g., propranolol) block beta-2 receptors, causing severe bronchoconstriction. Use cardioselective beta-1 blockers (e.g., metoprolol) with extreme caution if clinically required.